TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
NEO

NeoGenomics Inc

Healthcare · Diagnostics & Research

19.40$ -2.5% vs. previous close Closing price · As of: Sep 21, 2026

Statements

Income Statement

NeoGenomics Inc (NEO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 727 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement NEO
Line item 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
0.3 0.0 0.1 0.4 0.6 1.9 6.5 12 20 29 34 43 60 66 87 100 244 240 277 409 444 484 510 592 661 727
0.1 0.2 0.5 0.6 1.2 2.8 5.5 9.4 14 19 24 33 35 46 56 134 138 149 212 259 297 322 347 370 445
0.2 0.0 -0.1 -0.1 0.0 0.7 3.7 6.0 11 15 16 19 27 32 41 44 110 102 127 197 186 187 188 245 290 283
0.0 0.5 2.3 2.4 2.7 4.2 4.6 3.6 3.0 8.5 8.2 22 30 27 31 37
1.1 0.4 0.4 0.7 1.5 3.6 9.1 12 10 11 13 16 17 24 34 64 89 85 128 144 221 211 209 226 273
1.1 8.1 0.5 0.4 0.7 1.5 3.6 9.1 12 17 19 20 26 29 38 49 96 99 117 184 200 306 346 352 382 349
-1.0 -8.1 -0.6 -0.5 -0.7 -0.8 0.1 -3.1 -0.9 -1.7 -3.0 -0.4 1.2 3.2 2.2 -5.6 2.6 2.9 10 13 -14 -119 -158 -108 -92 -66
0.0 0.0 0.2 0.0 0.0 0.2 0.3 0.0 0.3 0.5 0.7 0.8 1.1 1.0 0.9 0.9 10.0 5.5 6.2 3.7 7.0 8.2 7.6 6.9 6.6 3.8
-1.0 -0.8 -1.0 -0.1 -3.1 -1.1 -2.2 -3.3 0.0 0.1 2.2 1.3 -4.5 -7.4 -2.7 3.8 3.6 -14 -15 -159 -97 -81 -110
0.0 0.2 0.0 0.1 0.2 -0.1 0.2 0.2 0.0 -0.7 0.8 1.1 0.2 0.2 -2.0 -1.7 -2.3 1.2 -4.4 -18 -6.7 -15 -9.1 -1.9 -2.2
-1.0 -8.1 -0.6 -0.5 -0.8 -1.0 -0.1 -3.4 -1.4 -2.2 -3.3 -1.2 0.1 2.0 1.1 -2.5 -6.1 -0.4 2.6 8.0 4.2 -8.3 -144 -88 -79 -108
-0.9 -7.8 -0.8 -0.4 -0.6 -0.6 0.4 -2.6 -0.1 -0.5 -1.2 1.7 5.0 7.6 7.9 3.5 25 27 32 38 35 46 -82 -18 -1.5 -39

Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?